Research Trials
If you have any questions or are interested in participating in one of our clinical research studies, please call us at 402.955.2691 or email us at clinicaltrials@nebraskacancer.com.
-
Cancer Type:
-
Biomarker:
-
Phase:
-
Keyword:
-
RMC-LUNG-101
(Subprotocol C) A Platform Study of RAS(ON) Inhibitor Combinations in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)Cancer Type: Lung NSCLC
Biomarkers: RAS G12D-mutated
Phase: 1b/2
-
RYZ101-301, ACTION -1
A Phase Ib/3 global, randomized, controlled, open-label trial comparing treatment with Actinium Ac225 dotatate (RYZ101) to standard of care therapy in subjects with inoperable, advanced, somatostatin receptor expressing (SSTR+) gastroentero pancreatic neuroendocrine tumors that have progressed following prior treatment with 177Lu-Dotatate or 177Lu-DOTATOC Ac225 dotatate vs SOCCancer Type: Theranostics, Neuroendocrine
Lines of Therapy: 2, 3
Biomarkers: SSTR+
Phase: 1b, 3, Theranostic
View Details on ClinicalTrials.gov
-
OM-GRPR1
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic GRPR-expressing TumorsCancer Type: Solid tumor
Lines of Therapy: 2
Biomarkers: GRPR
Phase: 1
-
MBRC-201-001
A multicenter, open-label phase 1/2 dose-finding, safety, and pharmacokinetic study of MBRC-201, an anti-GRP78 DXD antibody-drug conjugate, in advanced refractory solid tumorsCancer Type: Solid tumor
Lines of Therapy: 2L+
Biomarkers: GRP78
Phase: 1
-
eVOLVE, Lung 02
Phase 3, Parallel Randomized Study to determine the efficacy of Volrustomig (MEDI5752) plus chemotherapy versus Pembrolizumab plus chemotherapty in first line patients with Metastatic NSCLCCancer Type: Lung NSCLC
Lines of Therapy: 1
Phase: 3
View Details on ClinicalTrials.gov
-
C5851005
Randomized, Phase 3, Open-Label Study To Evaluate PF-08046054/SGN-PDL1V Vs Docetaxel In Adult Participants With Previously-Treated Programmed Cell Death Ligand (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)Cancer Type: Lung NSCLC
Lines of Therapy: 2
Biomarkers: PD-L1
Phase: 3
View Details on ClinicalTrials.gov
-
BNT327-05
Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy versus placebo with chemotherapy in participants with previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) whose tumor PD-L1 status is considered negative.Cancer Type: BREAST
Lines of Therapy: 1
Biomarkers: TNBC
Phase: 3
-
AMG-757-20240178
A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in combination with Durvalumab, Carboplatin and Etoposide versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)Cancer Type: SCLC
Lines of Therapy: 1
Biomarkers: DLL3
Phase: 3
-
AstraZeneca Triton
A Phase 3b, Study to assess the efficacy of Durvalumab plus Trememlimumab vs Pembrolizumab in combination with platinum based chemotherapy for 1st line treatment in metastatic NSCLC patients with non-squamous histology who have mutations and/or co-mutations in STK11, KEAP1, or KRASCancer Type: Lung NSCLC
Biomarkers: STK11, KEAP1, KRAS
Phase: 3
View Details on ClinicalTrials.gov
-
BetaBart_US-101
A Phase 1/2a Dose Escalation and Expansion Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177Lu-BetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients with Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors.Cancer Type: Solid tumor
Lines of Therapy: 2
Biomarkers: B7-H3
Phase: 1
